ImmuPharma Stock Price, News & Analysis (LON:IMM)

GBX 161 -0.25 (-0.16 %)
(As of 12/18/2017 04:00 PM ET)
Previous CloseGBX 161
Today's RangeGBX 160 - GBX 167.69
52-Week RangeGBX 37.62 - GBX 175.35
Volume270,898 shs
Average Volume377,484 shs
Market Capitalization£208.76 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About ImmuPharma (LON:IMM)

ImmuPharma logoImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The Company's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The Company's research operations are in France.

Receive IMM News and Ratings via Email

Sign-up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorBio Therapeutic Drugs
SymbolLON:IMM
CUSIPN/A
Phone+44-20-71524080

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX (0.04)
Net IncomeN/A
Net Margins-3,507.40%
Return on Equity-101.24%
Return on Assets-86.98%

Miscellaneous

EmployeesN/A
Outstanding Shares129,670,000

ImmuPharma (LON:IMM) Frequently Asked Questions

What is ImmuPharma's stock symbol?

ImmuPharma trades on the London Stock Exchange (LON) under the ticker symbol "IMM."

Where is ImmuPharma's stock going? Where will ImmuPharma's stock price be in 2017?

4 brokers have issued 12-month price targets for ImmuPharma's stock. Their predictions range from GBX 100 to GBX 237. On average, they expect ImmuPharma's stock price to reach GBX 174.75 in the next year. View Analyst Ratings for ImmuPharma.

Who are some of ImmuPharma's key competitors?

Who are ImmuPharma's key executives?

ImmuPharma's management team includes the folowing people:

  • Robert Henri Zimmer M.D., Ph.D., President, Chief Scientific Officer, Director
  • Dimitri F. Dimitriou, Chief Executive Officer, Director
  • Tracy Weimar, Vice President - Operations and Finance, Company Secretary
  • Timothy McCarthy, Non-Executive Chairman of the Board (Age 60)
  • Stephane Robert Mery, Non-Executive Director (Age 50)

How do I buy ImmuPharma stock?

Shares of ImmuPharma and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ImmuPharma's stock price today?

One share of ImmuPharma stock can currently be purchased for approximately GBX 161.

How big of a company is ImmuPharma?

ImmuPharma has a market capitalization of £208.76 million.

How can I contact ImmuPharma?

ImmuPharma's mailing address is 50 Broadway, LONDON, SW1H 0BL, United Kingdom. The company can be reached via phone at +44-20-71524080.


MarketBeat Community Rating for ImmuPharma (IMM)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  142 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  192
MarketBeat's community ratings are surveys of what our community members think about ImmuPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ImmuPharma (LON:IMM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 174.75GBX 154GBX 150.67GBX 147.33

ImmuPharma (LON:IMM) Consensus Price Target History

Price Target History for ImmuPharma (LON:IMM)

ImmuPharma (LON:IMM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
12/12/2017FinnCapInitiated CoverageBuyGBX 237View Rating Details
11/2/2017Northland SecuritiesReiterated RatingBuyGBX 181View Rating Details
9/21/2017Northland Capital PartnersReiterated RatingBuyGBX 181View Rating Details
4/20/2017Panmure GordonReiterated RatingBuyGBX 100View Rating Details
(Data available from 12/18/2015 forward)

Earnings

Earnings History for ImmuPharma (LON:IMM)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

ImmuPharma (LON:IMM) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for ImmuPharma (LON:IMM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ImmuPharma (LON IMM)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

ImmuPharma (LON IMM) News Headlines

Source:
DateHeadline
ImmuPharma Plc :IMM-GB: Earnings Analysis: For the six months ended June 30, 2017 : November 22, 2017ImmuPharma Plc :IMM-GB: Earnings Analysis: For the six months ended June 30, 2017 : November 22, 2017
finance.yahoo.com - November 21 at 8:01 PM
ImmuPharma Nets Over GBP5.0 Million In Completed Lanstead Agreement (ALLISS) - London South East (blog)ImmuPharma Nets Over GBP5.0 Million In Completed Lanstead Agreement (ALLISS) - London South East (blog)
www.lse.co.uk - October 6 at 11:12 PM
Is This A Catalyst To Buy ImmuPharma plc (AIM:IMM)?Is This A Catalyst To Buy ImmuPharma plc (AIM:IMM)?
finance.yahoo.com - October 4 at 5:22 PM
Northland Securities Reaffirms Buy Rating for ImmuPharma PLC (IMM)Northland Securities Reaffirms Buy Rating for ImmuPharma PLC (IMM)
www.americanbankingnews.com - October 1 at 9:52 AM
ImmuPharma Prepares Regulatory Filings Ahead Of Lupuzor Trial ResultsImmuPharma Prepares Regulatory Filings Ahead Of Lupuzor Trial Results
www.morningstar.co.uk - September 26 at 10:30 AM
ImmuPharma PLC (IMM) Stock Rating Reaffirmed by Northland SecuritiesImmuPharma PLC (IMM) Stock Rating Reaffirmed by Northland Securities
www.americanbankingnews.com - September 23 at 12:44 PM
Immupharma Confident As Phase III Lupuzor Trial On TrackImmupharma Confident As Phase III Lupuzor Trial On Track
www.morningstar.co.uk - September 22 at 11:57 PM
ImmuPharma PLC (IMM) Stock Rating Reaffirmed by Northland Capital PartnersImmuPharma PLC (IMM) Stock Rating Reaffirmed by Northland Capital Partners
www.americanbankingnews.com - September 21 at 3:10 PM
Is ImmuPharma plc (AIM:IMM) Undervalued?Is ImmuPharma plc (AIM:IMM) Undervalued?
finance.yahoo.com - September 6 at 7:48 PM
ImmuPharma PLC (LON:IMM) PT Raised to GBX 181 at Northland SecuritiesImmuPharma PLC (LON:IMM) PT Raised to GBX 181 at Northland Securities
www.americanbankingnews.com - July 1 at 12:36 PM
ImmuPharma Recruits And Doses 200 Patients In Phase III Lupuzor TrialImmuPharma Recruits And Doses 200 Patients In Phase III Lupuzor Trial
www.morningstar.co.uk - June 30 at 7:58 PM
IMM. Reading back t-IMM. Reading back t-
www.lse.co.uk - June 24 at 11:18 PM
ImmuPharma 2016 Loss Widens As It Progresses Lupus Phase III TrialImmuPharma 2016 Loss Widens As It Progresses Lupus Phase III Trial
www.morningstar.co.uk - June 2 at 8:09 AM
UPDATE: ImmuPharma Raises GBP4.1 Million, Seeks Partners For Lupuzor (ALLISS)UPDATE: ImmuPharma Raises GBP4.1 Million, Seeks Partners For Lupuzor (ALLISS)
www.morningstar.co.uk - March 11 at 12:07 AM
BRIEF-ImmuPharma says update on lupuzor pivotal phase iii studyBRIEF-ImmuPharma says update on lupuzor pivotal phase iii study
www.reuters.com - January 25 at 7:18 PM
Update on Lupuzor Pivotal Phase III Study - London South East (registration) (blog)Update on Lupuzor Pivotal Phase III Study - London South East (registration) (blog)
www.lse.co.uk - December 23 at 11:10 PM
Legal & General Buys 3.4% Stake In Junior Drug Firm ImmuPharma (ALLISS)Legal & General Buys 3.4% Stake In Junior Drug Firm ImmuPharma (ALLISS)
www.morningstar.co.uk - November 9 at 6:56 AM
Close of Accelerated BookbuildClose of Accelerated Bookbuild
www.lse.co.uk - October 22 at 5:18 PM
ImmuPharma Investor To Place Shares, Company To Raise GBP800,000 (ALLISS)ImmuPharma Investor To Place Shares, Company To Raise GBP800,000 (ALLISS)
www.morningstar.co.uk - October 21 at 5:40 PM

SEC Filings

ImmuPharma (LON:IMM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

ImmuPharma (LON IMM) Stock Chart for Monday, December, 18, 2017

Loading chart…

This page was last updated on 12/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.